News & Events

Shanghai, September 17, 2025 — ChemExpress (688131.SH), Mabwell Bioscience (688062.SH) and Insilico Medicine officially announced the signing of a strategic cooperation agreement.The three parties, based on the principles of complementary strengths, resource sharing, collaborative innovation, and mutual trust, will jointly establish a novel ADC compound library covering hundreds of targets, screen and advance next-generation ADC candidate molecules, and accelerate the industrialization of innovative ADCs.

Highlights

Through this three-way collaboration, we have pioneered a new "ABC" (AI+BioTech/BioPharma+ CRO/CDMO) model for ADC drug development—integrating AI power, Biotech/Biopharma drive, and CRO/CDMO implementation to form a deep synergy across the value chain.

Strategic Significance

We believe this innovative model marks an important step forward in ADC drug development. By integrating ChemExpress’s expertise in payload-linker chemistry, conjugation & GMP manufacturing with Mabwell’s antibody platform and Insilico’s cutting-edge AI drug discovery capabilities, we will accelerate the development of innovative ADCs. This will bring safer and more effective treatment options to patients worldwide sooner.

In addition, ChemExpress will also be present at the upcoming 16th World ADC San Diego 2025, sharing our latest insights and innovations with global partners.

Featured Presentation

Our Senior Vice President Dr. Tangqing Li will deliver a presentation on Day 2.
Topic: Understanding Key CMC Considerations for Linker-Payload Development in ADCs.

We warmly invite you to visit our booth, meet with our experts, and explore new opportunities for collaboration in ADC innovation.